Syon Capital LLC Grows Position in Danaher Co. (NYSE:DHR)

Syon Capital LLC increased its position in shares of Danaher Co. (NYSE:DHR) by 54.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,960 shares of the conglomerate’s stock after buying an additional 2,460 shares during the quarter. Syon Capital LLC’s holdings in Danaher were worth $1,610,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its stake in shares of Danaher by 18.6% in the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock valued at $6,185,203,000 after purchasing an additional 3,905,449 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Danaher by 10.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock valued at $3,876,694,000 after purchasing an additional 1,619,586 shares during the last quarter. Capital International Investors grew its stake in shares of Danaher by 9.1% in the 4th quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after purchasing an additional 1,334,781 shares during the last quarter. Northern Trust Corp grew its stake in shares of Danaher by 1.7% in the 3rd quarter. Northern Trust Corp now owns 8,100,722 shares of the conglomerate’s stock valued at $2,009,789,000 after purchasing an additional 134,905 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Danaher in the 4th quarter valued at approximately $1,752,382,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Transactions at Danaher

In related news, SVP Brian W. Ellis sold 4,000 shares of the business’s stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total value of $1,000,040.00. Following the transaction, the senior vice president now owns 29,830 shares in the company, valued at $7,457,798.30. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the transaction, the director now owns 116,202 shares in the company, valued at $28,304,483.16. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Brian W. Ellis sold 4,000 shares of the business’s stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total value of $1,000,040.00. Following the completion of the transaction, the senior vice president now owns 29,830 shares in the company, valued at approximately $7,457,798.30. The disclosure for this sale can be found here. Insiders sold 148,783 shares of company stock valued at $37,536,717 over the last quarter. Company insiders own 11.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. TD Cowen lifted their target price on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Bank of America lifted their price target on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research note on Wednesday, April 24th. Jefferies Financial Group assumed coverage on Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price target on the stock. HSBC raised Danaher from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Finally, Barclays boosted their price target on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $269.29.

Danaher Trading Down 0.1 %

DHR stock traded down $0.16 during trading on Friday, reaching $254.85. 3,097,194 shares of the stock traded hands, compared to its average volume of 2,930,997. The business’s 50 day moving average price is $253.48 and its 200-day moving average price is $244.30. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $269.11. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. The firm has a market capitalization of $188.76 billion, a PE ratio of 43.19, a P/E/G ratio of 3.90 and a beta of 0.85.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter in the prior year, the business earned $2.36 earnings per share. The company’s revenue was down 2.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.42%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s payout ratio is 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.